Voxelotor
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Sickle Cell Disease
Conditions
Sickle Cell Disease, Sickle Cell Anemia
Trial Timeline
Dec 21, 2020 → Sep 13, 2022
NCT ID
NCT04400487About Voxelotor
Voxelotor is a approved stage product being developed by Pfizer for Sickle Cell Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT04400487. Target conditions include Sickle Cell Disease, Sickle Cell Anemia.
What happened to similar drugs?
3 of 20 similar drugs in Sickle Cell Disease were approved
Approved (3) Terminated (10) Active (8)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03943615 | Pre-clinical | Completed |
| NCT04724421 | Pre-clinical | Completed |
| NCT06023199 | Phase 2 | Active |
| NCT05018728 | Phase 2 | Terminated |
| NCT04400487 | Approved | Completed |
| NCT04247594 | Phase 2 | Terminated |
| NCT04188509 | Phase 3 | Terminated |
| NCT03573882 | Phase 3 | Terminated |
| NCT03036813 | Phase 3 | Completed |
| NCT02850406 | Phase 2 | Terminated |
Competing Products
20 competing products in Sickle Cell Disease